Short answer
Jade Biosciences, Inc. (JBIO) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces Jade Biosciences’ financial results for the quarter ended September 30, 2026.
Jade Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces Jade Biosciences’ financial results for the quarter ended September 30, 2026
- Results details are contained in Exhibit 99.1, the furnished earnings release
Item EX-99.1 · Exhibit EX-99.1
- Q3 net loss $35.1M, up from $25.2M, reflecting accelerating investment in clinical development
- Cash, cash equivalents and investments $475.7M, supporting operations and capital needs into Q4 2028
- JADE101 Phase 3 EVERGREEN trial in IgA nephropathy expected to start Q4 2026, advancing the lead program toward registration
- JADE101 Phase 2 interim data expected Q2 2027, with JADE201 and JADE301 data also anticipated during 2027
- R&D expense $30.8M, up $8.8M year over year, while weighted-average common shares increased to 71.8M from 39.6M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Jade Biosciences, Inc. 8-K filings
Get the next JBIO 8-K as it lands
Follow JBIO for push alerts, or ask the research agent what this filing means.